The measurement of serum cholesterol, with which the major part of the clinical literature on cholesterol is concerned, represents only one facet of the body metabolism of cholesterol. Hence, methods of measuring the metabolism of cholesterol in the body tissues of man would undoubtedly be useful. Over the past few years, techniques utilizing labeled isotopes have been developed to measure the body miscible pool of a variety of substances, including sodium, potassium, water, and uric acid (1, 2) . But the ability to measure a miscible pool of cholesterol by isotope dilution principles has been questioned as a result of studies indicating that the disappearance of labeled cholesterol from the plasma proceeds at a series of decreasing exponential rates (rather than a single rate) for periods of as long as 50 days (3) . However, when the curve for disappearance from plasma of C14-cholesterol specific radioactivity is followed for periods ranging from 4 to 7 months, as has been done in this investigation as well as in another recently reported study (4) , it is evident that the plasma cholesterol specific activity eventually does decline at an exponential rate, suggesting that a body cholesterol miscible pool and turnover rate may be determined from these curves. Furthermore, post-mortem tissue studies in patients who have died at vary- ing intervals after receiving C14-cholesterol have indicated that a miscible tissue pool of cholesterol that is exchangeable with the serum cholesterol does exist in man (5) . These observations have been utilized to measure and compare the body cholesterol miscible pools and turnover rates in a group of normal and hypercholesterolemic individuals by following the rate of disappearance of labeled cholesterol from the plasma for 4 to 7 months after its intravenous administration.
MATERIAL AND METHODS
Five normal ambulatory subj ects with serum cholesterol levels less than 250 mg per 100 ml and seven ambulatory patients with hypercholesterolemia were included in the study. The hypercholesterolemia in two of the patients was associated with the nephrotic syndrome. One hypercholesterolemic patient had clinical and laboratory signs of myxedema which had been induced by propylthiouracil therapy for severe angina pectoris, and one other patient had familial hypercholesterolemia with xanthomatoses and coronary heart disease. The remaining three patients with hypercholesterolemia also had coexistent essential hypertension. All patients selected for the study had relatively stable serum cholesterol levels with variations from the mean not greater than 10 per cent during the course of these studies. The dietary intake was unrestricted throughout the period of investigation.
Tracer doses of 5 to 30 ,c of 4-C14-cholesterol with a specific activity of 37.7 /Ac per mg were administered intravenously to all subjects according to methods previously described (5) . Samples of venous blood were collected at 1-to 10-day intervals over a total period of 125 to 212 days after administration of the labeled cholesterol. The plasma was separated from the red blood cells and analyzed for free and total cholesterol content and radioactivity as previously described (5) . The free and ester cholesterol specific activities were calculated from these values. In two of the subjects these studies were repeated 12 and 14 months after the initial in- jection of C4-cholesterol. In the patient with familial Duplicate 5-ml aliquots of each 24-hour urine collechypercholesterolemia and xanthomatoses, xanthelasmata tion were decolorized with activated charcoal and anawere surgically removed 62 days after administration of lyzed for total C4 radioactivity in a Tri-Carb liquid scin-C14-cholesterol and the C'4-cholesterol specific activity of tillation spectrometer after addition of 15 ml of scintilthe xanthelasmata was determined. lation solution.' In two of the subjects, complete stool collections were made over periods of 65 and 72 days, respectively, and RESULTS complete urine collections over 15 days. The urine collections were terminated after 15 days, since no C" 4 A summary and statistical analysis of the reradioactivity was measurable in the urine after the first sults are tabulated in Tables I and II. week of study. All stools were collected in cardboard 1. Rate of disappearance of C'4-cholesterol from containers, weighed, and then frozen. Pooled samples representing 3-to 5-day collection periods were hoe s m T mogenized in ethanol in a Waring Blendor and duplicate free and ester C'4-cholesterol specific activity of a aliquots of the homogenate were extracted three times representative subject is illustrated in Figure 1 . with ethanol; 1-to 2-ml aliquots of the extract were layered in planchets which were then dried and weighed.
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1 Prepared as follows: 4.0 g of 2,5-diphenyloxazole The total C'4 content of the stool samples was deter-(PPO), 0.25 g of 1,4-di-2-(5-phenyloxazolyl)-benzene mined in a windowless gas-flow counter with appropriate (POPOP), and 50.0 g naphthalene were made up to 1 L corrections for absorption.
with p-dioxane. In the group studied, the plasma free cholesterol specific activity reached a peak between 3 and 24 hours after labeled cholesterol administration whereas the ester cholesterol specific activity was maximal between the second and fourth days. The rate at which both free and ester cholesterol specific activities decreased was relatively rapid at first, with cholesterol specific activities at the end of 2 weeks generally less than 25 per cent of the peak plasma specific activities. From the third week to between the sixth and eighth weeks of the study, there was a gradually diminishing rate of decrease of cholesterol specific activity from the plasma. After the eighth week, until the termination of the study at 18 to 32 weeks, the decay curve of plasma cholesterol specific activity fell at a slow rate which remained exponential throughout the remainder of the study. The The xanthelasmata of the patient with familial hypercholesterolemia had a specific activity that was 96 per cent of the plasma cholesterol specific activity 62 days after labeled cholesterol administration. The skin overlying the xanthelasmata in this patient had a cholesterol specific activity that was 102 per cent of the plasma cholesterol specific activity, indicating that complete equilibration between skin and plasma cholesterol was present at 62 days.
3. Cholesterol turnover rate. The half-time disappearance of cholesterol averaged 72 days and ranged from 58 to 100 days in the 12 patients studied. The calculated amount of exchangeable cholesterol turned over per day averaged 1.9 and ranged from 1.0 to 3.2 g. The t, of the normal subjects averaged 65 days and ranged from 58 to 75 days, as compared with a mean t4 of 76 days and range of 63 to 100 days in the hypercholesterolemic group. The patient with myxedema had the slowest turnover rate of cholesterol, with a t4 of 100 days. The remaining t4 values of the hypercholesterolemic subjects were comparable to the values observed in the normal group. No significant correlation was present between the concentration of serum cholesterol and the turnover rate of cholesterol or between the size of the miscible pool and the turnover rate of cholesterol.
4. Stool and urinary excretion of C14 radioactivity. The stool excretion of total C14 radioactivity was greatest during the first week of the study and gradually decreased with time. In Patient R.L. (Figure 1 ), 43 per cent of the total injected C14 radioactivity was recovered in the stools during the first 72 days after labeled cholesterol administration. In the first 15 days the total urinary excretion of C14 radioactivity was 0.2 per cent of the injected dose with no measurable radioactivity present after the fifth day of study. The combined stool and urinary excretion of C14 radioactivity accounted for approximately 88 per cent of the labeled cholesterol turned over per day as calculated from the tj value of 74 days which was measured from the plasma specific activity decay curve.
In Patient H.L. 45 per cent of the injected C14 radioactivity was present in the stools over the first 65 days after cholesterol administration while 0.1 per cent of the total dose was recovered in the urine over the first 15 days. The total stool and urinary excretion of radioactivity represented approximately 82 per cent of the total labeled cholesterol turned over as calculated from the tj value of 59 days.
5. Reproducibility of studies. Repeat measurements of cholesterol turnover rate and miscible pool in Subjects H.L. and R.M. after 12 and 14 months, respectively, gave results similar to those obtained in the original studies of these patients. In Subject H.L. (see Figure 2) 
DISCUSSION
The rate of disappearance from the plasma of C14-labeled cholesterol has been studied extensively over varying intervals (3) (4) (5) (6) (7) . However, greatly differing turnover times for cholesterol have been reported, ranging from t4 values of 5 to 110 days, depending upon the length of time the studies were carried out and the portion of the plasma specific activity curve used to calculate the turnover rates. To explain the varying turnover rates which have been reported, Hellman, Rosenfeld and Gallagher have pointed out that, over periods of as long as 50 days, the cholesterol may disappear from the plasma at a series of exponential rates rather than at a single one so that no true body turnover rate could be expressed from the plasma disappearance curves during this period (3). Their studies have been confirmed by Kurland, Lucas and Freedberg (4) and by the present investigation. Both of these latter studies have also demonstrated that if the plasma cholesterol specific activity is followed over longer periods, its curve of disappearance eventually does decline at an exponential rate. An explanation of why a prolonged period of study is necessary for measurement of a true body turnover rate of cholesterol is obtained from the post-mortem studies concerning the equilibration of cholesterol between the plasma and tissues (5) . These studies have shown that this equilibration is generally a slow process and does not approach completion for periods of a month or more in some of the exchanging tissue compartments. Thus, the decrease of C14-cholesterol from the plasma prior to the time when complete equilibration with the tissues was attained would reflect the continuing distribution of cholesterol between the blood and tissues as well as the metabolic turnover of cholesterol within the miscible pool. In view of the similar cholesterol specific activities in the plasma and tissues from 1 to 7 months after labeled cholesterol administration and the exponential rate of decay of plasma cholesterol specific activity during this same interval, it appears that an equilibrium state between the plasma and tissue cholesterol persists during this period-. For these reasons, a portion of the plasma decay curve extending from the period beginning 6 to 8 weeks after labeled cholesterol administration to the end of the study at approximately 18 to 32 weeks was used to calculate the body turnover rate and miscible pool of cholesterol.
The cholesterol turnover rates varied from tk values of 58 to 100 days. In this heterogeneous group of patients with hypercholesterolemia, the mean tj was somewhat greater than that in the normal individuals. The slowest turnover rate of cholesterol was found in the myxedematous patient. However, with the exception of this patient, the tj values of the hypercholesterolemic individuals were generally within the normal range. A slow turnover rate of cholesterol in myxedema has been described previously (4) and may reflect a decrease in the rate of biliary and stool excretion of cholesterol and its degradation products (8) .
The The cholesterol in the xanthelasmata appears to be a part of the miscible pool of cholesterol, and the presence of these subcutaneous deposits of cholesterol may be a reflection of a high Echol level.
The total amount of exchangeable cholesterol that was turned over per day in these subjects ranged from 1.0 to 3.2 g daily. Stool and urinary excretion of C14 radioactivity accounted for 82 and 88 per cent of the calculated daily turnover of cholesterol in the two patients in whom these collections were made. Skin secretion of cholesterol, which represents one other significant source of sterol loss from the body was not measured in these patients, but it is estimated that 50 to 100 mg of cholesterol is secreted by the skin per day (13, 14) . This would represent approximately 3 to 7 per cent of the calculated daily turnover of exchangeable cholesterol in these two individuals, and if this estimated skin loss were added to the measured stool and urinary losses, the total would appear to account for approximately 90 per cent of the cholesterol turned over per day as calculated from the plasma cholesterol specific activity curves. These findings lend further support to the hypothesis that a body turnover rate of cholesterol is measured by these plasma disappearance curves. As has been reported previously, the C14 radioactivity that is administered in the form of labeled cholesterol appears to remain in the body mainly as a part of the cholesterol molecule (4, 15). In the stool, however, most of this cholesterol is excreted in the form of bile acids (16) .
The miscible pool of cholesterol that has been measured in this study appears to include the cholesterol in all the body tissues outside of the central nervous system. It had been shown previously that only negligible degrees of equilibration occur between the plasma and brain cholesterol during the interval used in these studies (4) . Since about 20 per cent of the total body sterol is estimated to be in the nervous system (17) , it appears that the miscible pool of cholesterol would constitute approximately 80 per cent of total body cholesterol.
SUMMARY AND CONCLUSIONS 1. Measurements of body cholesterol miscible pool and turnover rate have been carried out in normal and hypercholesterolemic subjects by studying the rate of disappearance of C14-cholesterol specific activity from the plasma over periods of 4 to 7 months after the intravenous administration of labeled cholesterol. 
